Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07223593 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Name: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease — clinical trial record (NCT07223593)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ATTAIN-PAD

StatusRecruiting

PhasePhase 3

SponsorEli Lilly and Company

Started2025-10-31

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.

Amendment history 3 changes detected by DataLookout

2026-08-07

Trial sites expanded: 154 → 157 locations

2026-07-19

Trial sites expanded: 150 → 154 locations

2026-07-08

Trial sites expanded: 140 → 150 locations

Trial Details

NCT Number	NCT07223593
Lead Sponsor	Eli Lilly and Company
Conditions	Peripheral Arterial Disease
Enrollment	1,205 participants
Start Date	2025-10-31
Primary Completion	2028-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-09-08